These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 7964893)
21. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping. An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966 [TBL] [Abstract][Full Text] [Related]
22. Association of metals with the risk and clinical characteristics of Parkinson's disease. Kim MJ; Oh SB; Kim J; Kim K; Ryu HS; Kim MS; Ayton S; Bush AI; Lee JY; Chung SJ Parkinsonism Relat Disord; 2018 Oct; 55():117-121. PubMed ID: 29891430 [TBL] [Abstract][Full Text] [Related]
24. Serological profiles of urate, paraoxonase-1, ferritin and lipid in Parkinson's disease: changes linked to disease progression. Ikeda K; Nakamura Y; Kiyozuka T; Aoyagi J; Hirayama T; Nagata R; Ito H; Iwamoto K; Murata K; Yoshii Y; Kawabe K; Iwasaki Y Neurodegener Dis; 2011; 8(4):252-8. PubMed ID: 21282940 [TBL] [Abstract][Full Text] [Related]
25. Cerebrospinal fluid selenium and chromium levels in patients with Parkinson's disease. Aguilar MV; Jiménez-Jiménez FJ; Molina JA; Meseguer I; Mateos-Vega CJ; González-Muñoz MJ; de Bustos F; Gómez-Escalonilla C; Ort-Pareja M; Zurdo M; Martínez-Para MC J Neural Transm (Vienna); 1998; 105(10-12):1245-51. PubMed ID: 9928893 [TBL] [Abstract][Full Text] [Related]
26. Tau protein concentrations in cerebrospinal fluid of non-demented Parkinson's disease patients. Molina JA; Benito-León J; Jiménez-Jiménez FJ; Ortí-Pareja M; Berbel A; Tallón-Barranco A; de Bustos F; Hernánz A Neurosci Lett; 1997 Dec; 238(3):139-41. PubMed ID: 9464639 [TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Parkinson's disease. Molina JA; de Bustos F; Jiménez-Jiménez FJ; Benito-León J; Ortí-Pareja M; Gasalla T; Tallón-Barranco A; Navarro JA; Arenas J; Enríquez-de-Salamanca R J Neural Transm (Vienna); 1997; 104(11-12):1287-93. PubMed ID: 9503274 [TBL] [Abstract][Full Text] [Related]
28. Restless legs syndrome in Parkinson disease: Clinical characteristics, abnormal iron metabolism and altered neurotransmitters. Piao YS; Lian TH; Hu Y; Zuo LJ; Guo P; Yu SY; Liu L; Jin Z; Zhao H; Li LX; Yu QJ; Wang RD; Chen SD; Chan P; Wang XM; Zhang W Sci Rep; 2017 Sep; 7(1):10547. PubMed ID: 28874701 [TBL] [Abstract][Full Text] [Related]
29. Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease. Tórsdóttir G; Kristinsson J; Sveinbjörnsdóttir S; Snaedal J; Jóhannesson T Pharmacol Toxicol; 1999 Nov; 85(5):239-43. PubMed ID: 10608487 [TBL] [Abstract][Full Text] [Related]
30. Serum levels of coenzyme Q10 in patients with Parkinson's disease. Jiménez-Jiménez FJ; Molina JA; de Bustos F; García-Redondo A; Gómez-Escalonilla C; Martínez-Salio A; Berbel A; Camacho A; Zurdo M; Barcenilla B; Enríquez de Salamanca R; Arenas J J Neural Transm (Vienna); 2000; 107(2):177-81. PubMed ID: 10847558 [TBL] [Abstract][Full Text] [Related]
31. Response to long-term deferoxamine therapy in thalassemia. Cohen A; Martin M; Schwartz E J Pediatr; 1981 Nov; 99(5):689-94. PubMed ID: 7299539 [TBL] [Abstract][Full Text] [Related]
32. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload. Hussain MA; Green N; Flynn DM; Hussein S; Hoffbrand AV Lancet; 1976 Dec; 2(7998):1278-80. PubMed ID: 63749 [TBL] [Abstract][Full Text] [Related]